Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions.
about
Immunogenicity to Biotherapeutics - The Role of Anti-drug Immune ComplexesInfliximab-Related Infusion Reactions: Systematic ReviewIncidence, Prevention and Management of Anti-Drug Antibodies Against Therapeutic Antibodies in Inflammatory Bowel Disease: A Practical Overview.Influence of anti-TNF immunogenicity on safety in rheumatic disease: a narrative review.Immunogenicity to biologics: mechanisms, prediction and reduction.Fcγ receptor IIIb polymorphism and use of glucocorticoids at baseline are associated with infusion reactions to infliximab in patients with rheumatoid arthritis.Adverse events of anti-tumor necrosis factor α therapy in ankylosing spondylitisFrom historical perspectives to modern therapy: a review of current and future biological treatments for Crohn's diseaseEvaluation of abatacept administered subcutaneously in adults with active rheumatoid arthritis: impact of withdrawal and reintroduction on immunogenicity, efficacy and safety (phase Iiib ALLOW study).B cell epitopes on infliximab identified by oligopeptide microarray with unprocessed patient sera.Sex-dimorphic adverse drug reactions to immune suppressive agents in inflammatory bowel disease.Circulating T cells to infliximab are detectable mainly in treated patients developing anti-drug antibodies and hypersensitivity reactionsThe effect of immunomodulators on the immunogenicity of TNF-blocking therapeutic monoclonal antibodies: a review.Acute infusion reactions induced by monoclonal antibody therapy.Immunogenicity of therapeutic proteins: the use of animal models.Allergy to monoclonal antibodies: cutting-edge desensitization methods for cutting-edge therapies.Infliximab for the treatment of psoriasis in the U.K.: 9 years' experience of infusion reactions at a single centre.Assessing immunogenicity of biosimilar therapeutic monoclonal antibodies: regulatory and bioanalytical considerations.Formation, clearance, deposition, pathogenicity, and identification of biopharmaceutical-related immune complexes: review and case studies.Optimized nonclinical safety assessment strategies supporting clinical development of therapeutic monoclonal antibodies targeting inflammatory diseases.Strategic characterization of anti-drug antibody responses for the assessment of clinical relevance and impact.Adverse reactions to biologic agents and their medical management.Investigating the potential side effects of anti-TNF therapy for rheumatoid arthritis: cause for concern?Comparison of immunogenicity test methods used in clinical studies of infliximab and its biosimilar (CT-P13).Immunogenicity of infliximab and adalimumab: what is its role in hypersensitivity and modulation of therapeutic efficacy and safety?From the bench to clinical practice: understanding the challenges and uncertainties in immunogenicity testing for biopharmaceuticals.Frequency and characteristics of infusion reactions during biosimilar infliximab treatment in inflammatory bowel diseases: results from Central European nationwide cohort.The safety of monoclonal antibodies in asthma.Rapid Drug Desensitization with Biologics: A Single-Center Experience with Four Biologics.The Value of In Vitro Tests to DiminishDrug Challenges.Understanding the Cautions and Contraindications of Immunomodulator and Biologic Therapies for Use in Inflammatory Bowel Disease.Immunologic evaluation of drug allergy.In vitro tests for drug hypersensitivity reactions: an ENDA/EAACI Drug Allergy Interest Group position paper.Effect of growth hormone and IgG aggregates on dendritic cells activation and T-cells polarization.Role of glucocorticoid-induced leucine zipper (GILZ) in inflammatory bone loss.How the immune system responds to therapeutic biological agents.No Correlations Between the Development of Specific IgA and IgM Antibodies Against Anti-TNF Blocking Agents, Disease Activity and Adverse Side Reactions in Patients with Rheumatoid Arthritis.The Immunogenicity of Branded and Biosimilar Infliximab in Rheumatoid Arthritis According to Th9-Related Responses.Pre-existing IgG antibodies cross-reacting with the Fab region of infliximab predict efficacy and safety of infliximab therapy in inflammatory bowel disease.IgE-mediated anaphylaxis and allergic reactions to idursulfase in patients with Hunter syndrome.
P2860
Q26766424-6598326B-C709-461C-B988-DA613ED228C2Q27013835-D8F63C55-83CB-4000-9225-094E76201CA4Q30235581-2D3D9349-570A-40C8-A357-69DFA7CA718BQ30240229-B0E11D3A-B678-4CAD-B906-BF8F34F8156BQ34296526-79CA555A-0E93-4CDD-9472-0245E40BFE04Q34462584-2B02757D-267F-4661-952E-A72DE03B747CQ35170882-8086666F-CEC8-4DC7-B775-D73F82DF3498Q35559305-450D457B-C59E-4E61-BC32-26772E984B17Q35601018-81166F8F-08D3-4D40-90DC-1ED4A5FDB1F7Q36223471-8095944E-26A9-413F-AAE9-A4CF55A093CCQ36492621-02EDDBE8-C1DE-482D-91D2-D296E58D2AD5Q37412095-76F15962-CB9E-4DCA-9783-3E6559009490Q37804483-5AC66D44-86A4-4DA7-9A6B-69CD20919201Q37821495-F3B4F53A-B134-4FEC-8A46-7FCE1ACFDE28Q37899800-078FDDD5-A84C-4B4E-B800-8DDA1D4519DDQ37965600-DD835652-8C6B-4B17-8C09-9D21CB359C58Q37992139-C0AD7132-6743-468E-B51B-E9169D7FE36DQ38083093-7618CE5E-B99D-46D9-A780-A6A682DF11CAQ38202541-C439B08C-4AA7-4420-8BCE-5901D96164BDQ38208275-B2868968-79FE-4307-81BF-68046B8A035DQ38232124-4C5F44A0-3974-4397-8209-7D186439E91AQ38238948-B143F871-2BE0-40A5-B843-D5FE5BB3CBDFQ38445319-5B3B8A72-3844-4A81-A5BE-162CBD44C894Q38591278-A73EBE33-B674-4B1D-ABC6-F5BD993D95ABQ38631012-A81B5617-0195-49BD-9B86-82CB59AAC65CQ38644644-8FEC1CFE-DB6B-4823-A832-9F55532EF161Q38786144-D7121F0F-5443-4582-8E93-C035C5727E9CQ38842153-9F46D45E-3A3F-4F9A-8624-0A2A9378F742Q39042503-82217F84-9BF5-4F96-B969-3CC7D7584FD3Q39356960-16314D47-3BEF-49F7-95B5-D98467E20210Q39435409-4BE659C2-550B-4285-BE86-21C34BEB5A52Q39558242-C8F83E00-7868-468F-9B09-E689B48BAE3BQ39909074-E20E4B3C-7968-4944-B6E8-34783206F7E4Q40514614-B965C147-7480-4699-9F2B-2BCB920C2F7CQ41236945-36B2F0C4-CD7E-48C4-888D-5DC7CC2CCAF7Q41882370-BA433C91-52D5-417C-89EE-292519740026Q42622733-A93A1A0B-E805-4642-A01E-12F43873E565Q43246232-D796DFBE-8E27-4206-BDD5-41117FF3FBDBQ43528474-D21926F8-DA7C-464A-9D2B-5F17CB3ECDB2Q43530570-67161302-5560-481C-961A-E9FF36F8CA31
P2860
Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions.
description
2009 nî lūn-bûn
@nan
2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Anti-infliximab IgE and non-Ig ...... severe anaphylactic reactions.
@ast
Anti-infliximab IgE and non-Ig ...... severe anaphylactic reactions.
@en
Anti-infliximab IgE and non-Ig ...... severe anaphylactic reactions.
@nl
type
label
Anti-infliximab IgE and non-Ig ...... severe anaphylactic reactions.
@ast
Anti-infliximab IgE and non-Ig ...... severe anaphylactic reactions.
@en
Anti-infliximab IgE and non-Ig ...... severe anaphylactic reactions.
@nl
prefLabel
Anti-infliximab IgE and non-Ig ...... severe anaphylactic reactions.
@ast
Anti-infliximab IgE and non-Ig ...... severe anaphylactic reactions.
@en
Anti-infliximab IgE and non-Ig ...... severe anaphylactic reactions.
@nl
P2093
P1433
P1476
Anti-infliximab IgE and non-Ig ...... severe anaphylactic reactions
@en
P2093
A Vultaggio
P Parronchi
S Romagnani
P304
P356
10.1111/J.1398-9995.2009.02280.X
P50
P577
2009-11-27T00:00:00Z